Delineate is building AI agents to design better clinical trials faster. This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential.
Delineate is a Y Combinator company in the Winter 2025 batch. Its directory entry describes it as: Agents for Accelerated Clinical Trial Design. The founders listed are Emily Nieves (Founder/CEO), Jawad Iqbal (Founder/CTO) (Y Combinator directory entry, February 11, 2025).
Sell to companies like Delineate? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2025-02-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Delineate.
Free to see. No signup.
More on Delineate and the records around it.
Get an email when Delineate changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Delineate raises, hires or launches. No email unless you switch it on.
Watch Delineate →Get the full cited report on Delineate
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Delineate: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Delineate is building AI agents to design better clinical trials faster. This is a $10B dollar market, where saving even 1 day along the process is equal to $1-5M in revenue potential. We process existing clinical trial research into specialized datasets saving scientists months of effort. Delineate is working with two of the largest pharmaceutical companies. With one of our customers, we are helping them get to the next phase of trials faster by creating the largest dataset on a drug class ever constructed.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Delineate: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Delineate covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist DelineateYou get an alert in MentionFox the next time this company shows up.
If you're behind Delineate: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Delineate. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-delineate